Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lenz Therapeutics, Inc.

NASDAQ: LENZ · Life Sciences · 3 alerts · CIK 1815776

Share price
$3.82Close, Nov 16
Market cap
$120M
Shares outstanding
31.42MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lenz Therapeutics, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Lenz Therapeutics Q3 2026 Results: Net Loss of $31M, Loss Widens

LENZ Therapeutics transitioned to a commercial-stage company following the FDA approval of VIZZ in July 2025, reporting its first product sales of $6.0 million for the nine months ended September 30, 2026. Despite the new revenue stream, the company saw a significant increase in net loss to $104.4 million for the same period, driven primarily by a surge in selling, general, and administrative expenses to $120.2 million.

Key figure
Net loss $31M
4:35 PM ET 8-K
Financial Results

Lenz Therapeutics Financial Results

LENZ Therapeutics reported Q3 2026 financial results featuring a 50% sequential increase in VIZZ product sales. Alongside results, the company announced a strategic reorganization reducing headcount by 75% to focus on consumer marketing and a leadership transition where CEO Eef Schimmelpennink will be succeeded by CFO Dan Chevallard as Interim CEO on December 1, 2026.

Term
Q3 2026

“Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates. We view these as promising indicators of our positive trajectory in this emerging market.”

Eef Schimmelpennink, President and Chief Executive Officer

“After nearly six years leading LENZ and more than 25 years in the biotechnology industry, I have decided to transition from my role as CEO effective December 1, 2026, to devote more time to other passions.”

Eef Schimmelpennink, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.